Open AccessIn Vivo Alemtuzumab Enables Haploidentical Human Leukocyte Antigen-Mismatched Hematopoietic Stem-Cell Transplantation Without Ex Vivo Graft Manipulation
Author(s) -
Yoshinobu Kanda,
Kiyohiro Oshima,
Yuki AsanoMori,
Koji Kandabashi,
Masahiro Nakagawa,
Mamiko SakataYanagimoto,
Koji Izutsu,
Akira Hangaishi,
Shiho Tsujino,
Seishi Ogawa,
Toru Motokura,
Shigeru Chiba,
Hisamaru Hirai
Publication year - 2005
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000158718.49286.14
Subject(s) - alemtuzumab , medicine , transplantation , cd52 , fludarabine , total body irradiation , hematopoietic stem cell transplantation , ex vivo , immunology , graft versus host disease , cumulative incidence , stem cell , gastroenterology , leukemia , surgery , in vivo , chemotherapy , biology , cyclophosphamide , genetics , microbiology and biotechnology
Alemtuzumab, a humanized monoclonal antibody directed against human CD52, has a strong lympholytic effect. This study evaluates the safety of unmanipulated peripheral blood stem-cell transplantation from two or three loci-mismatched related donors using alemtuzumab in vivo.